stockportfolio.pro
Eupraxia Pharmaceuticals Inc. (EPRX)
Healthcare · Biotechnology · NasdaqCM
Eupraxia Pharmaceuticals Inc. revenue & earnings — last 4 fiscal years
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Gross profit | — | — | — | — |
| Net income | $-18.49M | $-28.22M | $-25.50M | $-38.58M |
| Net margin | — | — | — | — |
Source: Eupraxia Pharmaceuticals Inc. SEC filings (10-K).
Explore 4 years of Eupraxia Pharmaceuticals Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track EPRX in your portfolio →
Eupraxia Pharmaceuticals Inc. financial history by metric
About Eupraxia Pharmaceuticals Inc.
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company's product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of gastrointestinal tract, such as eosinophilic esophagitis. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.
Eupraxia Pharmaceuticals Inc. — frequently asked questions
What is Eupraxia Pharmaceuticals Inc.'s revenue?
Eupraxia Pharmaceuticals Inc. (EPRX) reported revenue of $0 for fiscal year 2025, according to its SEC filings.
Is Eupraxia Pharmaceuticals Inc. profitable?
No — EPRX reported a net loss of $-38.58M in fiscal 2025.
What is EPRX's P/E ratio?
Eupraxia Pharmaceuticals Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Eupraxia Pharmaceuticals Inc. have?
As of fiscal year 2025, EPRX carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Eupraxia Pharmaceuticals Inc.'s market cap?
Eupraxia Pharmaceuticals Inc. (EPRX) has a market capitalization of about $386.41M, based on the latest data in our nightly-refreshed cache.
When does Eupraxia Pharmaceuticals Inc.'s fiscal year end?
EPRX's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Eupraxia Pharmaceuticals Inc.'s official SEC filings (10-K and 10-Q), covering 4 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.